Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 4/20 | 0.67 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.62 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210192 | 0.90 | PTGER4 (0.70) | PTGER2PTGER4PTGER3PTGER1 | |
| SCHEMBL10210602 | 0.90 | PTGER4 (0.54) | PTGER2PTGER4 | |
| SCHEMBL11929363 | 0.90 | PTGER4 (0.73) | PTGER2PTGER4 | |
| SCHEMBL10210375 | 0.89 | PTGER4 (0.55) | PTGER2PTGER4PTGER3 | |
| SCHEMBL10210448 | 0.88 | PTGER4 (0.55) | PTGER2PTGER4PTGER3 | |
| SCHEMBL10210097 | 0.88 | PTGER2 (0.63) | PTGER2PTGER4PTGER3PTGER1 | |
| SCHEMBL2211302 | 0.85 | PTGER2 (0.67) | PTGER2PTGER4PTGER3PTGER1 | |
| SCHEMBL2211296 | 0.85 | PTGER2 (0.67) | PTGER2PTGER4PTGER3PTGER1 | |
| SCHEMBL10204007 | 0.84 | PTGER4 (0.75) | PTGER2PTGER4PTGER3 | |
| SCHEMBL4988522 | 0.84 | PTGER4 (0.61) | PTGER2PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| EP-2255829-A2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | Ono Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | PTGER2 3/4885PTGER4 1/4885PTGER3 4/4885 |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | PTGER2 3/4885PTGER4 1/4885PTGER3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.